Walden Group Healthcare M&A Blog

  • FDA Grants Breakthrough Device Designation to Medtronic’s Minimally Invasive Valiant TAAA Stent Graft System

    10/10/2019
    The new Valiant TAAA Stent Graft System is designed to repair a thoracoabdominal aortic aneurysm (TAAA). A TAAA causes swelling of the aorta, which extends from the chest into the abdomen. Commonly, TAAA affects the branch arteries supplying blood to various internal organs. The condition accounts for approximately 15% of all thoracic aneurysms....
    Read More
  • Celgene to Sell Blockbuster Drug to Amgen for $13.4b

    08/26/2019
    Amgen Inc., a $23b multinational biopharmaceutical company is buying the worldwide rights to Otezla® from Celgene Corporation, a $13b developer of therapies for cancer and inflammatory diseases, for $13.4b. The acquisition complements Amgen's existing inflammation franchise of innovative biologics and biosimilar products. Otezla® (apremilast) is...
    Read More
  • Exact Sciences to buy Genomic Health for $2.8b

    7/29/2019
    Exact Sciences Corp, a $454m molecular diagnostics company is acquiring Genomic Health Inc, a $394m cancer detection company for $2.8b. The deal joins two of the strong brands in molecular and cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth; and forms a first class commercial, research,...
    Read More
  • Cantel Medical to Acquire Hu-Friedy for $725m

    07/30/2019
    Cantel Medical Corp., a $880m manufacturer of medical equipment announced plans to buy Hu-Friedy Mfg. Co., a maker of dental instruments and reprocessing equipment for $725m. The deal helps build out a portfolio of infection prevention solutions including consumables, instrumentation and workflow management programs for dental practitioners while...
    Read More
  • AbbVie to Buy Allergan for $63b

    06/25/2019
    AbbVie Inc., a $32.75b pharmaceutical company agreed to buy Allergan plc, an Ireland-based $15.79b pharmaceutical company for $63b. The latest merger in an industry where huge premiums are being paid to incease growth prospects. The deal gives AbbVie Botox, but doesn’t involve a huge pipeline of blockbuster drugs. Allergan does diversify AbbVie...
    Read More